Prostate cancer patients may ditch painful hormone shots, study hints
NCT ID NCT03565835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether men with advanced prostate cancer could safely stop their regular hormone injections (like leuprolide) and rely only on the pills abiraterone and prednisone to keep testosterone at very low levels. 31 men participated. The goal was to see if testosterone stayed low enough to control the cancer without the shots. The results help doctors understand if this simpler pill-only approach is possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a blood filtering technique reveal more about prostate cancer spread?
- Can a vaccine plus immune booster tackle resistant prostate cancer?
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?